Clinical trial
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
NCT00270413 · Universitaire Ziekenhuizen KU Leuven, Other · Completed
Key facts
| NCT number | NCT00270413 |
|---|---|
| Title | SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer |
| Official title | A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction |
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | SU11248 |
| Enrollment | 19 |
| Start date | Jan 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Dec 26, 2005 |
| Last update posted | Nov 22, 2022 |
| Countries | Belgium |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: